Granite Point Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Granite Point Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-43,195	Closed	-$78K	–	127
2018 Q2	$78K	Sell	43,195 -98,594	-70%	-$198K	0.01%	116
2018 Q1	$334K	Sell	141,789 -120,587	-46%	-$283K	0.03%	91
2017 Q4	$494K	Buy	262,376 +211,455	+415%	+$462K	0.05%	80
2017 Q3	$127K	Hold	50,921	–	–	0.03%	95
2017 Q2	$140K	Sell	50,921 -27,080	-35%	-$75.7K	0.03%	99
2017 Q1	$235K	Sell	78,001 -12,058	-13%	-$34.2K	0.07%	78
2016 Q4	$284K	Hold	90,059	–	–	0.23%	71
2016 Q3	$307K	Hold	90,059	–	–	0.12%	80
2016 Q2	$206K	Buy	+90,059	New	+$221K	0.09%	77
2015 Q4	$346K	Hold	104,687	–	–	0.05%	72
2015 Q3	$253K	Sell	104,687 -4,817	-4%	-$12.5K	0.17%	78
2015 Q2	$321K	Sell	109,504 -32,982	-23%	-$128K	0.09%	85
2015 Q1	$572K	Hold	142,486	–	–	0.21%	69
2014 Q4	$429K	Buy	+142,486	New	+$385K	0.2%	67

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Granite Point Capital Management's LCTX Position: Q3 2018 in Review

Granite Point Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2018, closing a stake of 43,195 shares — an estimated $78K sold.

Granite Point Capital Management first reported a position in LCTX in Q4 2014 and held it in 14 quarters. The position peaked at $572K in Q1 2015. 106 funds tracked by Wall St. Rank hold LCTX as of Q3 2018.

Granite Point Capital Management reported no remaining Lineage Cell Therapeutics position as of Q3 2018 after selling out during the quarter.
Granite Point Capital Management sold 43,195 Lineage Cell Therapeutics shares in Q3 2018, an estimated $78K.
Granite Point Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2014 and held it in 14 quarters.
Granite Point Capital Management's Lineage Cell Therapeutics position peaked at $572K in Q1 2015.
106 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2018.

Based on Granite Point Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.